Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
?Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.
?11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.
?Combination continues to exhibit a favorable tolerability profile.
?Top-line results from the selection portion of Verastem?s registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.
- Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC;
- Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib
- Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022
- Enrollment Complete in Selection Phase (Part A) of RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022
In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
the reverse stock split will become effective at 5:00 p.m. Eastern Time on May 31, 2023 (the "Effective Time") and the Company expects that its common stock will open for trading on June 1, 2023 on the Nasdaq Capital Market on a split-adjusted basis under the Company?s existing trading symbol "VSTM".
New drug combination offers ovarian cancer breakthrough
...The revolutionary treatment has been shown to significantly shrink tumours in almost half of patients with the disease
...The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the ?fantastic? and ?very exciting? results from clinical trials of the drug combination, presented at the world?s largest cancer conference this weekend, showed it was ?far more effective? than any available option for patients.
...The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.
Trial results show almost half the patients on the new drug combination ? 45% ? saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment ? trametinib, which has a response rate of 26%.
Thread abonnieren
